Quantbot Technologies LP Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Quantbot Technologies LP raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 193.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,661 shares of the biopharmaceutical company's stock after acquiring an additional 5,047 shares during the quarter. Quantbot Technologies LP's holdings in Halozyme Therapeutics were worth $366,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its holdings in shares of Halozyme Therapeutics by 17.5% during the 4th quarter. Teacher Retirement System of Texas now owns 37,516 shares of the biopharmaceutical company's stock valued at $1,794,000 after purchasing an additional 5,594 shares in the last quarter. Lindenwold Advisors INC purchased a new position in Halozyme Therapeutics in the fourth quarter valued at $239,000. Vinva Investment Management Ltd acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $138,000. Xponance Inc. boosted its stake in shares of Halozyme Therapeutics by 6.0% during the 4th quarter. Xponance Inc. now owns 18,454 shares of the biopharmaceutical company's stock worth $882,000 after acquiring an additional 1,051 shares in the last quarter. Finally, Intech Investment Management LLC grew its position in shares of Halozyme Therapeutics by 147.6% during the 4th quarter. Intech Investment Management LLC now owns 139,410 shares of the biopharmaceutical company's stock valued at $6,665,000 after acquiring an additional 83,105 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,200 shares of company stock valued at $1,786,668. Insiders own 2.90% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded up $1.15 during mid-day trading on Wednesday, reaching $63.02. The company's stock had a trading volume of 1,571,854 shares, compared to its average volume of 1,383,175. The stock has a 50-day moving average of $59.62 and a two-hundred day moving average of $54.90. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a market capitalization of $7.79 billion, a P/E ratio of 18.37, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HALO. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.